AR076856A1 - Lenalidomida polimorfa y proceso para su preparacion - Google Patents
Lenalidomida polimorfa y proceso para su preparacionInfo
- Publication number
- AR076856A1 AR076856A1 ARP100101577A ARP100101577A AR076856A1 AR 076856 A1 AR076856 A1 AR 076856A1 AR P100101577 A ARP100101577 A AR P100101577A AR P100101577 A ARP100101577 A AR P100101577A AR 076856 A1 AR076856 A1 AR 076856A1
- Authority
- AR
- Argentina
- Prior art keywords
- preparation
- lenalidomide
- polymorph
- crystalline
- theta
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
La presente solicitud se relaciona con una forma cristalina de la lenalidomida, procesos para su preparacion, y el uso de la forma polimorfica en la preparacion de composiciones farmacéuticas. Reivindicacion 1: Lenalidomida cristalina con un patron de difraccion de rayos-x en polvo que comprende uno o más picos localizados en las posiciones 8,29; 25,9 y 27,5 0,2 grados 2-theta.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IN1079CH2009 | 2009-05-08 | ||
US22652409P | 2009-07-17 | 2009-07-17 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR076856A1 true AR076856A1 (es) | 2011-07-13 |
Family
ID=43050836
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP100101577A AR076856A1 (es) | 2009-05-08 | 2010-05-07 | Lenalidomida polimorfa y proceso para su preparacion |
Country Status (2)
Country | Link |
---|---|
AR (1) | AR076856A1 (es) |
WO (1) | WO2010129636A2 (es) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
UA83504C2 (en) | 2003-09-04 | 2008-07-25 | Селджин Корпорейшн | Polymorphic forms of 3-(4-amino-1-oxo-1,3 dihydro-isoindol-2-yl)-piperidine-2,6-dione |
TWI475014B (zh) * | 2009-09-17 | 2015-03-01 | Scinopharm Taiwan Ltd | 固體形態的3-(4-胺基-1-側氧基-1,3-二氫-異吲哚-2-基)-哌啶-2,6-二酮及其製造方法 |
WO2011061611A1 (en) * | 2009-11-19 | 2011-05-26 | Ranbaxy Laboratories Limited | Process for the preparation of form b of lenalidomide |
EP2688649B1 (en) * | 2011-03-23 | 2019-04-10 | Hetero Research Foundation | A polymorph of lenalidomide |
WO2016024286A2 (en) * | 2014-08-11 | 2016-02-18 | Avra Laboratories Pvt. Ltd. | An improved process for synthesis of lenalidomide |
ES2811110T3 (es) * | 2015-08-27 | 2021-03-10 | Grindeks Jsc | Composición farmacéutica capaz de la incorporación de Lenalidomida en diversas modificaciones cristalinas |
TWI664172B (zh) * | 2016-08-25 | 2019-07-01 | 大陸商浙江海正藥業股份有限公司 | 來那度胺的晶型及其製備方法和用途 |
CN112999224B (zh) * | 2021-03-03 | 2022-09-16 | 天津大学 | 一种布洛芬载来那度胺复合颗粒及其制备方法 |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5635517B1 (en) * | 1996-07-24 | 1999-06-29 | Celgene Corp | Method of reducing TNFalpha levels with amino substituted 2-(2,6-dioxopiperidin-3-YL)-1-oxo-and 1,3-dioxoisoindolines |
UA83504C2 (en) * | 2003-09-04 | 2008-07-25 | Селджин Корпорейшн | Polymorphic forms of 3-(4-amino-1-oxo-1,3 dihydro-isoindol-2-yl)-piperidine-2,6-dione |
-
2010
- 2010-05-05 WO PCT/US2010/033661 patent/WO2010129636A2/en active Application Filing
- 2010-05-07 AR ARP100101577A patent/AR076856A1/es unknown
Also Published As
Publication number | Publication date |
---|---|
WO2010129636A2 (en) | 2010-11-11 |
WO2010129636A3 (en) | 2011-03-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR076856A1 (es) | Lenalidomida polimorfa y proceso para su preparacion | |
BRPI1013426A2 (pt) | organismos para produção de 1,3-butanodiol | |
CL2013000322A1 (es) | Compuestos derivados de piperidina sustituida; proceso de preparacion; composicion farmaceutica y su uso para producir un efecto antiproliferativo y/o proapoptotico. | |
BRPI0911024A2 (pt) | "método para produzir macarrão instantâneo" | |
AR096046A1 (es) | Derivados de 2,2-difluoropropanamida de metil bardoxolona, formas polimórficas y métodos de uso | |
SV2011004019A (es) | 2-acetamido-5-aril-1,2,4-triazolonas sustituidas y su uso | |
MY162411A (en) | Crystalline forms of a macrolide, and uses therefor | |
EP2639636A4 (en) | PHOTOSENSITIVE RESIN COMPOSITION OF POSITIVE TYPE | |
AR077203A1 (es) | Forma polimorfica d del acetato de bazedoxifeno, composiciones farmaceuticas que la contienen metodo para prepararla y uso del mismo para tratar enfermedades mediadas por moduladores selectivos de receptores estrogenicos (serms) | |
AR061311A1 (es) | Procesos para preparar clorhidrato de cinacalcet y formas polimorficas del mismo | |
CR7876A (es) | Forma cristalina alfa del ranelato de estroncio, procedimiento para su preparacion y composiciones farmaceuticas que la contienen | |
BRPI0823256A2 (pt) | Uso de sacarose como substrato para produção fermentativa de 1,2-propanodiol | |
BRPI0915439A2 (pt) | composição tópica para o tratamento de ceratose actínica | |
SI2220152T1 (sl) | Postopek za pripravo sestavka premreĹľevalnega sredstva | |
CO6630130A2 (es) | Inhibidor de inmunoproteasoma de péptido epoxicetona cristalino | |
EP2639637A4 (en) | PHOTOSENSITIVE RESIN COMPOSITION OF POSITIVE TYPE | |
EA201200616A1 (ru) | Производные 2-оксо-1-пирролидинилимидазотиадиазола | |
CR20130594A (es) | Monohidrato de derivados de aza-adamantano | |
BRPI0814261A2 (pt) | Micor-organismos termofílicos para produção de etanol | |
AR075418A1 (es) | Polimorfo cristalino de 3-{[5-(azetidin-1-ilcarbonil)pirazin-2-il]oxi}-5-{[(1s)-1-metil-2-(metiloxi)etil]oxi}-n-(5-metilpirazin-2-il)benzamida,composiciones farmaceuticas que los contienen, proceso para prepararla y uso de las mismas para el tratamiento de la diabetes tipo ii y/u obesidad. | |
BRPI0811548A2 (pt) | Forma polimórfica de um composto, composição farmacêutica, e, processo para sintetizar uma forma polimórfica de um composto | |
AR085543A1 (es) | Agomelatina, una forma cristalina vii, sus metodos de preparacion, aplicaciones y composiciones farmaceuticas | |
FI20070134A0 (fi) | Menetelmä pelkistysainekoostumuksen valmistamiseksi | |
ES2489467T3 (es) | Polimorfo novedoso del clorhidrato del éster (6-dimetilaminometil-2-naftalenílico) del ácido (4-hidroxicarbamoilfenil)-carbámico | |
EP2520690A4 (en) | RUTHENIUM COMPLEX MIXTURE, MANUFACTURING METHOD, FILM-FORMING COMPOSITION, RUTHENIUM-HOLDING FILM, AND PRODUCTION METHOD THEREFOR |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |